BR0316487A - Método todo de tratamento da rejeição de transplantes - Google Patents

Método todo de tratamento da rejeição de transplantes

Info

Publication number
BR0316487A
BR0316487A BR0316487-0A BR0316487A BR0316487A BR 0316487 A BR0316487 A BR 0316487A BR 0316487 A BR0316487 A BR 0316487A BR 0316487 A BR0316487 A BR 0316487A
Authority
BR
Brazil
Prior art keywords
transplant rejection
whole method
treating transplant
treating
whole
Prior art date
Application number
BR0316487-0A
Other languages
English (en)
Inventor
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0316487A publication Critical patent/BR0316487A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"MéTODO TODO DE TRATAMENTO DA REJEIçãO DE TRANSPLANTES". Método de tratamento ou prevenção da rejeição crónica de órgãos transplantados compreendendo a administração de um composto de fórmula em que R¬ 1¬, R¬ 2¬ e R¬ 3¬ são como definido acima.
BR0316487-0A 2002-11-26 2003-11-17 Método todo de tratamento da rejeição de transplantes BR0316487A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42978402P 2002-11-26 2002-11-26
PCT/IB2003/005229 WO2004047843A1 (en) 2002-11-26 2003-11-17 Method of treatment of transplant rejection

Publications (1)

Publication Number Publication Date
BR0316487A true BR0316487A (pt) 2005-10-11

Family

ID=32393587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316487-0A BR0316487A (pt) 2002-11-26 2003-11-17 Método todo de tratamento da rejeição de transplantes

Country Status (15)

Country Link
US (1) US7250420B2 (pt)
EP (1) EP1572213A1 (pt)
JP (1) JP2006509000A (pt)
KR (1) KR20050086784A (pt)
CN (1) CN1717236A (pt)
AU (1) AU2003276591A1 (pt)
BR (1) BR0316487A (pt)
CA (1) CA2507392A1 (pt)
MX (1) MXPA05005576A (pt)
MY (1) MY137250A (pt)
NZ (1) NZ539901A (pt)
PL (1) PL378246A1 (pt)
TW (1) TW200418482A (pt)
WO (1) WO2004047843A1 (pt)
ZA (1) ZA200503811B (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
WO2004047843A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
US20050137684A1 (en) * 2003-12-17 2005-06-23 Pfizer Inc Stent with therapeutically active drug coated thereon
AU2004305317A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
CA2604161A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) * 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ATE497496T1 (de) 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101549876B1 (ko) 2007-06-13 2015-09-03 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
PL2265607T3 (pl) 2008-02-15 2017-07-31 Rigel Pharmaceuticals, Inc. Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
EP2288610B8 (en) 2008-03-11 2016-10-12 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
BRPI0910921B1 (pt) 2008-04-16 2022-06-21 Portola Pharmaceuticals, Inc Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2011001259A (es) * 2008-08-01 2011-03-15 Biocryst Pharm Inc Derivados de piperidina como inhibidores jak3.
SI2384326T1 (sl) 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine
EP2421867B1 (en) 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (zh) 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CN103732226B (zh) 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2897962A1 (en) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
UA120834C2 (uk) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
BE640616A (pt) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JP2983254B2 (ja) * 1989-06-14 1999-11-29 武田薬品工業株式会社 ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
WO1997002262A1 (en) 1995-07-05 1997-01-23 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US5965563A (en) 1995-11-14 1999-10-12 Pharmacia & Upjohn S.P.A. Aryl and heteroaryl purine compounds
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (de) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT938486E (pt) 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EP0972197A1 (en) * 1997-03-24 2000-01-19 PHARMACIA & UPJOHN COMPANY Method for identifying inhibitors of jak2/cytokine receptor binding
CA2326383A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
TR200003719T2 (tr) 1998-06-19 2001-03-21 Pfizer Products Inc. Pirolo[2,3-d]Pirimidin bileşikleri
CA2337999A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
JP2002526500A (ja) 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
CA2412560C (en) * 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
KR20040006555A (ko) * 2002-07-12 2004-01-24 삼성전자주식회사 액정 표시 장치
WO2004047843A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
AU2004305317A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection

Also Published As

Publication number Publication date
WO2004047843A1 (en) 2004-06-10
MY137250A (en) 2009-01-30
AU2003276591A1 (en) 2004-06-18
US7250420B2 (en) 2007-07-31
EP1572213A1 (en) 2005-09-14
ZA200503811B (en) 2006-07-26
NZ539901A (en) 2007-09-28
US20040116449A1 (en) 2004-06-17
TW200418482A (en) 2004-10-01
JP2006509000A (ja) 2006-03-16
CA2507392A1 (en) 2004-06-10
KR20050086784A (ko) 2005-08-30
MXPA05005576A (es) 2005-07-27
CN1717236A (zh) 2006-01-04
PL378246A1 (pl) 2006-03-20

Similar Documents

Publication Publication Date Title
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
BRPI0417803A (pt) método de tratamento de rejeição de transplantes
BRPI0416909A (pt) método de tratamento de aterosclerose
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
NO20052787L (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
BR0316496A (pt) Quinolin-, isoquinolin-, e quinazolin-oxialquilamidas e seu emprego como fungicidas
BR0214035A (pt) Composto
BR0312479A (pt) Composição de tratamento dos cabelos e/ou couro cabeludo, método de tratamento de caspa e uso de óleo de manjericão
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
CR7864A (es) Piridodiacinas como fungicidas de plantas
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
BRPI0413740A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
BRPI0512310A (pt) compostos quìmicos
DE60206171D1 (de) Kaliumkanal-modulierende imidazolderivate
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
NO20032406D0 (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/519, A61P 37/00

Ipc: A61K 31/519 (2011.01), A61P 37/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.